The vast majority of astrocytomas are not hereditary. Only about 5% of gliomas (the broader category that includes astrocytomas) are considered familial, meaning they affect two or more members of the same family. The remaining 95% are sporadic, appearing with no clear inherited genetic cause. That said, a small number of hereditary syndromes do raise the risk, and having a first-degree relative with a glioma roughly doubles your own risk compared to the general population.
Why Most Astrocytomas Are Not Inherited
Astrocytomas develop from star-shaped brain cells called astrocytes. When doctors classify these tumors today, they look at specific genetic mutations within the tumor itself, particularly whether the tumor carries a mutation called IDH. These mutations are somatic, meaning they arise spontaneously in the brain tissue during a person’s lifetime rather than being passed down from a parent. A tumor’s genetics matter enormously for prognosis and treatment, but they’re distinct from the kind of inherited gene changes that run in families.
Researchers have identified roughly 25 spots in the human genome that are associated with a modest increase in glioma risk, with each one raising the odds only slightly (between 1.1 and 3.5 times). No single gene variant acts as a strong on-off switch for astrocytoma in the way that, say, BRCA mutations influence breast cancer risk. For most people diagnosed with an astrocytoma, there is no identifiable inherited cause.
Hereditary Syndromes That Raise the Risk
While uncommon, several inherited conditions do predispose people to astrocytomas. If you or a family member has one of these syndromes, the connection to brain tumors is well established.
Neurofibromatosis Type 1
NF1 is the most common inherited tumor predisposition syndrome, affecting roughly 1 in 2,500 to 3,000 people worldwide. Children with NF1 are especially prone to low-grade gliomas, most often pilocytic astrocytomas that grow along the optic pathway. About 15 to 20% of children with NF1 develop an optic pathway tumor, though only 30 to 50% of those children experience symptoms, and only about a third ultimately need treatment. Adults with NF1 can develop higher-grade gliomas, but this is less common.
Li-Fraumeni Syndrome
Li-Fraumeni syndrome is caused by inherited mutations in the TP53 gene, which normally acts as a powerful tumor suppressor. Central nervous system tumors account for 9 to 14% of all cancers in people with this syndrome, and glioblastomas and astrocytomas are the most frequent brain tumor types among them. The cumulative risk of developing a CNS tumor by age 70 is about 6% for women and 19% for men with the condition. Li-Fraumeni also raises the risk of breast cancer, bone cancers, soft-tissue sarcomas, and adrenal gland tumors, so a family history featuring multiple cancer types at young ages is a hallmark.
Tuberous Sclerosis Complex
TSC is caused by mutations in either the TSC1 or TSC2 gene and affects multiple organ systems. One specific type of astrocytoma, called a subependymal giant cell astrocytoma (SEGA), develops in about 20% of people with TSC based on imaging studies. These tumors grow near the fluid-filled spaces of the brain and can sometimes block the flow of cerebrospinal fluid. In one large study, 14% of TSC patients with a SEGA developed hydrocephalus (a dangerous buildup of fluid in the brain). SEGAs in TSC patients tend to appear at younger ages, with an average age of 31 compared to 37 for TSC patients without this tumor type.
Turcot Syndrome
Turcot syndrome links inherited colorectal cancer with brain tumors. Patients with one form of the syndrome (caused by DNA mismatch repair gene mutations) are predisposed to glioblastomas, while those with another form are more prone to medulloblastomas. Astrocytomas and other brain tumor types can also occur, though less frequently.
What “Familial” Means in Practice
When researchers describe about 5% of gliomas as familial, they typically mean that more than one person in the same family has been diagnosed, often before age 50. Having a first-degree relative (parent, sibling, or child) with a glioma doubles your risk. That sounds significant, but context matters: gliomas are rare to begin with, so doubling a small number still results in a small number. For the average person, the lifetime risk of being diagnosed with a malignant brain tumor is well under 1%.
In many familial cases, researchers cannot identify a specific inherited syndrome or single gene responsible. The increased risk likely comes from a combination of common genetic variants, each contributing a small amount, potentially interacting with environmental factors that remain poorly understood.
When Genetic Evaluation Makes Sense
Certain patterns in a family’s medical history suggest a possible hereditary component worth investigating. These include being diagnosed with an astrocytoma at an unusually young age, having multiple family members with brain tumors, or having a personal or family history that includes several different cancer types, especially the combinations seen in Li-Fraumeni syndrome (breast cancer, bone tumors, soft-tissue sarcomas, adrenal tumors alongside brain tumors) or Turcot syndrome (colon cancer plus brain tumors).
If you have a known diagnosis of NF1 or tuberous sclerosis complex, your medical team will already be aware of the brain tumor risk. Children with NF1, for example, are typically monitored with regular eye exams and brain imaging to catch optic pathway gliomas early, since many of these tumors grow slowly and may never need treatment.
For families where two or more members have had gliomas without a known syndrome, a genetics specialist can review the family history, discuss whether testing for specific gene mutations is warranted, and help interpret the results. Genetic testing is most useful when it could change how you or your family members are monitored, not as a routine step for every astrocytoma diagnosis.
Somatic vs. Inherited Mutations
One source of confusion is that astrocytoma diagnosis now relies heavily on genetic markers found in the tumor itself. For example, the current classification system separates astrocytomas into IDH-mutant and IDH-wildtype categories based on mutations in the tumor tissue. These are somatic mutations: they happened in the brain cells that became cancerous and are not present in the rest of your body. They cannot be passed to your children. The genetic mutations doctors look for when diagnosing and grading your tumor are, in almost all cases, completely separate from the question of whether your family carries an inherited predisposition.
The inherited mutations that matter for heredity are germline mutations, present in every cell of the body from birth. These are the mutations found in syndromes like Li-Fraumeni (TP53), NF1, and tuberous sclerosis (TSC1/TSC2). If you carry one of these, each of your children has a 50% chance of inheriting it.